New York, NY -- (SBWIRE) -- 12/27/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Companhia Energetica Minas Gerais (ADR) (NYSE:CIG), Tower Group International, Ltd (NASDAQ:TWGP), Galena Biopharma Inc (NASDAQ:GALE), Supernus Pharmaceuticals Inc (NASDAQ:SUPN)
Companhia Energetica Minas Gerais (ADR) (NYSE:CIG) showed a volume of 1.57 million shares by the end of last trade whereas the average volume of the stock remained 2.99 million shares. The stock opened the session at $7.89 but then moved to $7.83. At that price, the stock showed a negative performance of -1.01%. Companhia Energetica de Minas Gerais Cemig is a Brazil-based holding company primarily engaged in the electricity sector. The Company is mainly active in the construction and operation of systems of production, transformation, transmission, distribution and commercialization of electric power. It is involved in the provision of telecommunication services, and purchase, transport and distribution of natural gas. It has a number of subsidiaries, including Cemig Geracao e Transmissao, which operates hydroelectric plants, thermoelectric plants, wind farms and transmission lines; Cemig Distribuicao SA,
Will CIG Get Buyers Even After The Recent Rally? Find Out Here
Tower Group International, Ltd (NASDAQ:TWGP) opened the session at $2.90 and closed the session at $2.88. Traded with volume of 1.59 million shares in the prior session and the average volume of the stock remained 2.99 million shares.
Galena Biopharma Inc (NASDAQ:GALE) opened the session at $4.03 and closed the session at $4.07. The stock showed a positive performance of 1.75% in previous trading session. Traded with volume of 1.55 million shares in the prior session and the average volume of the stock remained 6.51 million shares. The beta of the stock remained 1.10. Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors.
Why Should Investors Buy GALE After The Recent Gain? Just Go Here and Find Out
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) the stock decreased -5.13% and finished the session at $7.95. Traded with volume of 1.53 million shares in the prior session and the average volume of the stock remained 693,105.00 shares. Supernus Pharmaceuticals, Inc. (Supernus) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus’s two epilepsy product candidates are SPN-538 and Epliga.
Will SUPN Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)